



ZIOPHARM Oncology, Inc.
Investor Relations Department
One First Ave., Parris Building, # 34
Navy Yard Plaza
Boston, MA 02199
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: ZIOP

| | |
|---------------|----------------------------|
| Last Trade: | 6.07 |
| Trade Time: | 3:30 PM ET Sep 21, 2017 |
| Change: | -0.05 (-0.817%) |
| Day Range | 5.95 - 6.16 |
| 52-Week Range | 4.84 - 7.88 |
| Volume | 645,459 |


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse portfolio of treatments for people with cancer and graft-versus-host -disease. Our focus is on the development of cell and viral -therapies using a suite of technologies that employing novel gene expression, control and cell technologies to deliver safe, effective and scalable therapies.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Sep 18, 2017
[ZIOPHARM Oncology Announces Updated Findings from Phase 1 Study of Ad-RTS-hIL-12 + Velelimex in Recurrent Glioblastoma Presented at American Academy of Neurological Surgery Annual Meeting](#)

Sep 5, 2017
[ZIOPHARM to Present at the Rodman & Renshaw 19th Annual Global Investment Conference](#)

Sep 1, 2017
[ZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit](#)

Jul 31, 2017
[ZIOPHARM Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Recent Activities](#)

Jul 24, 2017
[ZIOPHARM Oncology to Host Second-Quarter 2017 Financial Results and Corporate Update Conference Call on July 31, 2017 at 4:30 p.m. ET](#)

Financials [\[View all \]](#)

Feb 16, 2017
[Annual Report \(10-K\)](#)

Apr 28, 2017
[Proxy Statement \(DEF 14A\)](#)

Jul 31, 2017
[Quarterly Report \(10-Q\)](#)

May 1, 2017
[Quarterly Report \(10-Q\)](#)

Nov 9, 2016
[Quarterly Report \(10-Q\)](#)